Lajara Rosemarie, Davidson Jaime A, Nikkel Carla C, Morris Tracy L
Endocr Pract. 2016 Jun;22(6):726-35. doi: 10.4158/EP151182.OR. Epub 2016 Feb 1.
To compare two methods of delivering intensified insulin therapy (IIT) in patients with type 2 diabetes inadequately controlled on basal insulin ± concomitant antihyperglycemic agents in a real-world clinical setting.
Data for this retrospective study were obtained using electronic medical records from a large multicenter diabetes system. Records were queried to identify patients transitioned to V-Go(®) disposable insulin delivery device (V-Go) or multiple daily injections (MDI) using an insulin pen to add prandial insulin when A1C was >7% on basal insulin therapy. The primary endpoint was the difference in A1C change using follow-up A1C results.
A total of 116 patients were evaluated (56 V-Go, 60 MDI). Both groups experienced significant glycemic improvement from similar mean baselines. By 27 weeks, A1C least squares mean change from baseline was -1.98% (-21.6 mmol/mol) with V-Go and -1.34% (-14.6 mmol/mol) with MDI, for a treatment difference of -0.64% (-7.0 mmol/mol; P = .020). Patients using V-Go administered less mean ± SD insulin compared to patients using MDI, 56 ± 17 units/day versus 78 ± 40 units/day (P<.001), respectively. Diabetes-related direct pharmacy costs were lower with V-Go, and the cost inferential from baseline per 1% reduction in A1C was significantly less with V-Go ($118.84 ± $158.55 per patient/month compared to $217.16 ± $251.66 per patient/month with MDI; P = .013).
Progression to IIT resulted in significant glycemic improvement. Insulin delivery with V-Go was associated with a greater reduction in A1C, required less insulin, and proved more cost-effective than administering IIT with MDI.
A1C = glycated hemoglobin ANCOVA = analysis of covariance CI = confidence interval CSII = continuous subcutaneous insulin infusion FPG = fasting plasma glucose IIT = intensified insulin therapy LSM = least squares mean MDI = multiple daily injections T2DM = type 2 diabetes mellitus TDD = total daily dose.
在真实临床环境中比较两种强化胰岛素治疗(IIT)方法,用于基础胰岛素±联合降糖药物治疗血糖控制不佳的2型糖尿病患者。
本回顾性研究的数据来自一个大型多中心糖尿病系统的电子病历。查询记录以识别在基础胰岛素治疗时糖化血红蛋白(A1C)>7%,转而使用V-Go(®)一次性胰岛素输注装置(V-Go)或胰岛素笔多次皮下注射(MDI)追加餐时胰岛素的患者。主要终点是根据随访A1C结果得出的A1C变化差异。
共评估了116例患者(56例使用V-Go,60例使用MDI)。两组均从相似的平均基线水平实现了显著的血糖改善。到27周时,使用V-Go的患者A1C自基线的最小二乘均值变化为-1.98%(-21.6 mmol/mol),使用MDI的患者为-1.34%(-14.6 mmol/mol),治疗差异为-0.64%(-7.0 mmol/mol;P = 0.020)。与使用MDI的患者相比,使用V-Go的患者平均胰岛素剂量更低(标准差),分别为56±17单位/天和78±40单位/天(P<0.001)。V-Go的糖尿病相关直接药房费用更低,且每降低1% A1C的基线成本推断显著低于MDI(每位患者每月118.84±158.55美元,而MDI为每位患者每月217.16±251.66美元;P = 0.013)。
进展至IIT可显著改善血糖。与使用MDI进行IIT相比,使用V-Go输注胰岛素可使A1C降低幅度更大,所需胰岛素更少,且更具成本效益。
A1C = 糖化血红蛋白;ANCOVA = 协方差分析;CI = 置信区间;CSII = 持续皮下胰岛素输注;FPG = 空腹血糖;IIT = 强化胰岛素治疗;LSM = 最小二乘均值;MDI = 多次皮下注射;T2DM = 2型糖尿病;TDD = 每日总剂量